NCT01517893View on ClinicalTrials.gov

Clinical Trial of Simvastatin to Treat Generalized Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
Vitiligo
Interventions
DRUG

Simvastatin

Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated

DRUG

Placebo

Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated

Trial Locations (1)

01655

University of Massachusetts Medical School Clinical Research Center, Worcester

All Listed Sponsors
lead

John Harris

OTHER

NCT01517893 - Clinical Trial of Simvastatin to Treat Generalized Vitiligo | Biotech Hunter | Biotech Hunter